OJAS  Vol.7 No.1 , January 2017
Evidence for Neurotoxicity from Quinoline Antimalaria Drugs: Four Personal Accounts
Abstract: Background: The adverse effects of mefloquine and other quinoline antimalaria drugs can be severe and long-lasting. We believe that the trigger for these effects may be drug-induced hepatocellular damage that causes, firstly, a spillage of retinoids into the circulation (and hence a direct toxic effect on the brain and other target organs), and secondly, disruption of the liver-thyroid axis (and hence a pattern of specific bipolar symptoms such as is often seen in thyroid disease). Methods: We sought recently-published lay accounts of adverse effects in users of quinoline antimalaria drugs, to test these lay descriptions against our hypothesis on the likely pathogenesis of these effects. Results: We found six lay accounts that described four different experiences of adverse effects arising from the prophylactic use of quinoline antimalaria drugs. All four travellers were healthy, at the start of travel. Two of the travellers experienced severe psychoses, and one had a mild psychosis. The fourth traveller, a serving US soldier, killed 16 unarmed Afghan civilians. Analysis of these accounts shows that, based on our hypothesis, all four travellers had at least one risk factor (most commonly, concurrent alcohol use), for developing a severe reaction to their quinoline antimalaria drug. Our hypothesis therefore predicted a severe adverse drug reaction in each of these four travellers. We also identified a hitherto unrecognized risk factor for developing a severe reaction to quinoline antimalaria drugs—namely, the concurrent use of anabolic steroids. Conclusions: Lay accounts of drug adverse effects can help initiate or further develop medical hypotheses of their pathogenesis. We advise that the quinoline class of antimalaria drugs should be prescribed cautiously, and that mefloquine should not now be prescribed for malaria prophylaxis, under any circumstances whatsoever. Where persistent adverse effects have resulted from the historical use of quinoline antimalaria drugs, we propose a five-point management strategy that we believe will in most cases cause symptoms to abate rapidly: 1) stop taking the quinoline drug; 2) stop alcohol, and stop all other liver-damaging drugs, including anabolic steroids, hormonal contraception, hormone replacement therapy, recreational drugs, antidepressants, anxiolytics and hypnotics; 3) maintain good hydration, using non-fluoridated drinking water; 4) temporarily eliminate dietary vitamin A; as an additional and optional therapeutic measure, 5) lower the concentration of circulating retinoids through phlebotomy, plasmapheresis or hirudotherapy.
Cite this paper: Croft, A. and Mawson, A. (2017) Evidence for Neurotoxicity from Quinoline Antimalaria Drugs: Four Personal Accounts. Open Journal of Animal Sciences, 7, 45-55. doi: 10.4236/ojas.2017.71005.

[1]   Croft, A.M. and Herxheimer, A. (2002) Adverse Effects of the Antimalaria Drug, Mefloquine: Due to Primary Liver Damage with Secondary Thyroid Involvement? BMC Public Health, 2, 6.

[2]   Mawson, A.R. (2013) Mefloquine Use, Psychosis, and Violence: A Retinoid Toxicity Hypothesis, Medical Science Monitor, 19, 579-583.

[3]   Croft, A.M., Whitehouse, D.P., Cook, G.C. and Beer, M.D. (2002) Expert Opinion: Safety Evaluation of the Drugs Available to Prevent Malaria. Expert Opinion in Drug Safety, 1, 19-27.

[4]   Ball, J.W., Dains, J.E., Flynn, J.A., Solomon, B.S. and Stewart, R.W. (2015) Seidel’s Physical Examination. 8th Edition, Elsevier, St Louis, Missouri.

[5]   Nevin, R.L. and Croft, A.M. (2016) Psychiatric Effects of Malaria and Anti-malarial Drugs: Historical and Modern Perspectives. Malaria Journal, 15, 332.

[6]   Landy, D. (1985) Pibloktoq (Hysteria) and Inuit Nutrition: Possible Implication of Hypervitaminosis A. Social Science and Medicine, 21, 173-185.

[7]   O’Donnell, J. (2004) Polar Hysteria: An Expression of Hypervitaminosis A. American Journal of Therapeutics, 11, 507-516.

[8]   Mawson, A.R., Eriator, I. and Karre, S. (2015) Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis (SJS/TEN): Could Retinoids Play a Causative Role? Medical Science Monitor, 21, 133-143.

[9]   van den Ende, E., van Gompel, A., Colebunders, R. and van den Ende, J. (1991) Mefloquine-Induced Stevens-Johnson Syndrome. The Lancet, 337, 683.

[10]   Phillips-Howard, P.A. and Buckler, W.J. (1988) Idiosyncratic Reaction Resembling Toxic Epidermal Necrolysis Caused by Chloroquine and Maloprim. British Medical Journal, 296, 1605.

[11]   Erickson, J.M. and Mawson, A.R. (2000) Possible Role of Endogenous Retinoid (Vitamin A) Toxicity in the Pathophysiology of Primary Biliary Cirrhosis. Journal of Theoretical Biology, 206, 47-54.

[12]   Mawson, A.R. (2013) Retinoids, Race and the Pathogenesis of Dengue Hemorrhagic Fever. Medical Hypotheses, 81, 1069-1074.

[13]   Rouve, N., Bagheri, H., Telmon, N. et al. (2011) Prescribed Drugs and Violence: A Case/ Noncase Study in the French PharmacoVigilance Database. European Journal of Clinical Pharmacology, 67, 1189-1198.

[14]   Thomas, K.H., Martin, R.M., Potokar, J., Pirmohamed, M. and Gunnell, D. (2014) Reporting of Drug Induced Depression and Fatal and Non-Fatal Suicidal Behaviour in the UK from 1998 to 2011. BMC Pharmacology and Toxicology, 15, 54.

[15]   Toovey, S. (2009) Mefloquine Neurotoxicity: a Literature Review. Travel Medicine and Infectious Disease, 7, 2-6.

[16]   MacLean, D.S. (2014) The Answer to the Riddle Is Me. Houghton Mifflin Harcourt, New York.

[17]   Harley, N. (2014) It Was Comedy or Insanity for Me, Says Merton. The Sunday Telegraph [London], 7 September 2014, 15.

[18]   Merton, P. (2014) Only When I Laugh. Ebury Press, London.

[19]   Ashton, A. (2014) Nobody Was That Crazy: Documents Show Soldiers Called Robert Bales “Paranoid” Well before Killings. Tacoma News Tribune, 5 July 2014, 7.

[20]   Owen, J. (2013) Lariam: History of Violence. The Independent [London], 27 September 2013, 5.

[21]   Rifkind, H. (2016) My Six Months of Madness (and the Drug That Helped Cause It). The Spectator [London], 26 May 2016, 26.

[22]   Aronson, J.K. and Hauben, M. (2006) Anecdotes That Provide Definitive Evidence. British Medical Journal, 333, 1267-1269.

[23]   Herxheimer, A., Healy, D. and Menkes, D.B. (2012) Case Histories as Evidence. International Journal of Risk and Safety in Medicine, 24, 23-29.

[24]   Jopp, D.S., Wozniak, D., Damarin, A.K., De Feo, M., Jung, S. and Jeswani, S. (2015) How Could Lay Perspectives on Successful Aging Complement Scientific Theory? Findings from a U.S. and a German Life-Span Sample. Gerontologist, 55, 91-106.

[25]   Anonymous (2015) FDA—Adverse Event Reporting System (FAERS). Adverse Event Report Filed with the Drug Manufacturer on 29 March 2012, Case ID: 8504150.

[26]   Dow, G., Bauman, R., Caridha, D., et al. (2006) Mefloquine Induces Dose-Related Neurological Effects in a Rat Model. Antimicrobial Agents and Chemotherapy, 50, 1045-1453.

[27]   Croft, A.M. (2007) A Lesson Learnt: The Rise and Fall of Lariam and Halfan. Journal of the Royal Society of Medicine, 100, 170-174.

[28]   Vinetz, J.M., Clain, J., Bounkeua, V., Eastman, R.T. and Fidock, D. (2011) Chemotherapy of Malaria. In: Brunton, L.L., Chabner, B.A. and Knollmann, B.C., Eds., Goodman & Gilman’s the Pharmacological Basis of Therapeutics, 12th Edition, McGraw-Hill, London, 1383-1418.

[29]   Xiong, X., Liu, J., He, W., et al. (2007) Dose-Effect Relationship between Drinking Water Fluoride Levels and Damage to Liver and Kidney Functions in Children. Environmental Research, 103, 112-116.

[30]   Elia, M. and Lanham-New, S.A. (2017) Nutrition. In: Kumar, P. and Clark, M., Eds., Kumar & Clark’s Clinical Medicine, 9th Edition, Elsevier Saunders, London, 183-218.

[31]   Rados, C. (2004) Beyond Bloodletting: FDA Gives Leeches a Medical Makeover. FDA Consumer, 38, 9.